GLP-1 & Metabolic Peptides

GLP-1 and metabolic research peptides for laboratory investigation of glucose homeostasis, energy regulation, and incretin receptor pathways. This collection includes selective GLP-1 receptor agonists, dual GLP-1/GIP agonists, triple agonist peptides, amylin receptor research compounds, small-molecule metabolic research tools, and laboratory reconstitution solvents used to study metabolic signalling, receptor crosstalk, and integrated pathway regulation in experimental models.

Research applications include receptor binding assays, glucose regulation studies, comparative agonist research, pharmacokinetic investigations, metabolic pathway analysis, and NNMT inhibition studies. All compounds are supplied as analytical reference standards for in-vitro laboratory use only.

Featured Research Compounds

Retatrutide: triple-agonist peptide for multi-receptor metabolic pathway research
Semaglutide: selective GLP-1 receptor agonist used in comparative incretin signalling research
Tirzepatide: dual GLP-1/GIP agonist for receptor crosstalk and pathway comparison studies
Cagrilintide: long-acting amylin analogue for adjacent metabolic signalling investigations
CagriSema 10mg: pre-blended GLP-1 and amylin receptor research blend for dual-pathway combination models
5-Amino-1MQ 50mg: selective NNMT inhibitor for NAD-related pathway and cellular energy expenditure research
Bacteriostatic Water 10mL: sterile reconstitution solvent for lyophilised peptide preparation in laboratory settings

Products in this collection may include batch-specific third-party documentation from independent laboratories depending on the product and batch. For detailed information about metabolic peptide research, visit our Research Peptides Guide.

Research Overview

GLP-1 and metabolic research compounds are commonly used in laboratory settings to investigate incretin signalling, receptor selectivity, pathway crosstalk, and broader metabolic regulation. This collection brings together compounds that sit across different points on that research spectrum — from selective GLP-1 receptor agonists through to dual- and triple-agonist peptides, combination research blends, and intracellular metabolic enzyme inhibitors.

Retatrutide is typically discussed in multi-receptor pathway research because it combines GLP-1, GIP, and glucagon receptor activity within a single peptide framework. Semaglutide is more narrowly associated with selective GLP-1 receptor research, while Tirzepatide is commonly examined in dual GLP-1/GIP models. Cagrilintide sits in a different position again, giving researchers a useful comparison point when studying adjacent amylin receptor signalling systems.

CagriSema 10mg extends this framework into combination-model research, providing a pre-blended GLP-1 and amylin receptor agonist blend for investigators studying dual-pathway interplay. 5-Amino-1MQ complements the collection from a different mechanistic angle, offering a selective NNMT inhibitor for researchers examining NAD-related metabolic pathways and cellular energy expenditure models.

Used together or independently, these compounds help create a more complete research framework for studying receptor overlap, signalling intensity, pathway divergence, and comparative model design.